CytoMed Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CytoMed Therapeutics (GDTC).

Price Target Range — 3 Quarters

Analyst Consensus

Consensus RatingSpeculative BuyAvg. Consensus PT$5Upside to Avg. PT+434.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 10, 2024	Benchmark	Bruce Jackson	Maintained	Speculative Buy	$5
Jun 11, 2024	Benchmark	Bruce Jackson	Maintained	Speculative Buy	$5
Dec 4, 2023	Benchmark	Bruce Jackson	Maintained	Speculative Buy	$5

Analyst Ratings News

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023

Benzinga Insights

PRO
Benchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5

Benchmark analyst Bruce Jackson initiates coverage on CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy rating and announces Price Target of $5.

Benzinga Newsdesk

Here's How BlackBerry Can Hit $500M In Software Revenue (And Win Over Investors)

Benzinga

CytoMed Therapeutics Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

CytoMed Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023

PRO
Benchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5

Here's How BlackBerry Can Hit $500M In Software Revenue (And Win Over Investors)

People Also Watch

People Also Watch

CytoMed Therapeutics Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

CytoMed Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBenchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PROBenchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PROBenchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023

PROBenchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5

Here's How BlackBerry Can Hit $500M In Software Revenue (And Win Over Investors)

People Also Watch

People Also Watch

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5